Covid-19 statement

Mundipharma Research – Covid-19 Updated: 14 May 2020 

As the world continues to take unprecedented action in response to the Coronavirus pandemic, nobody is left unaffected. At Mundipharma Research, we have responded at pace to ensure that we protect the health of our employees, partners, suppliers, and contractors, as a priority.

Since the outbreak of the virus, Mundipharma has taken all precautions and steps to ensure our supply chain remains robust and that provision of our medicines to the patients that depend on them continues uninterrupted. To date, there has been no disruption to our supply of medicines.

We have also worked tirelessly to ensure business continuity plans are in place, so that we can continue to deliver on our commitments to healthcare professionals, patient and professional groups, and external partners. This includes the rapid adoption of novel digital solutions across every part of our business, so that we can continue to deliver a high-quality service that meets the needs of healthcare professionals and our customers.

Our employees continue to be fully supported to work flexibly and are home-based wherever possible. For our people with essential roles that require them to be on-site, such as supply and manufacturing, we are actively following all relevant WHO and International guidelines to safeguard them. 

We know that the impact of this pandemic will be long-term and far-reaching. As such, we remain unwavering in our support – both internally and externally – during these most difficult of times.